Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00397033
Status:
COMPLETED
Last Update Posted:
2013-07-29
First Post:
2006-11-07
Brief Title:
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder
Sponsor:
Johnson Johnson Pharmaceutical Research Development LLC
Organization:
Johnson Johnson Pharmaceutical Research Development LLC
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release ER in patients who are experiencing an acute episode of schizoaffective disorder
Detailed Description:
Schizophrenia and schizoaffective disorder are closely related in terms of symptoms coexisting conditions and genetic risk In previous studies in patients with schizophrenia treatment with paliperidone extended-release ER improved psychotic symptoms as well as mood symptoms evaluated by anxietydepression and hostilityexcitement Positive and Negative Symptoms of Schizophrenia PANSS factor scores Therefore paliperidone ER may also be effective in treating symptoms of schizoaffective disorder Paliperidones limited potential for drug-drug interaction is particularly important in this patient population in which multiple drug therapy is relatively common This multicenter double-blind neither the patient nor the physician knows whether drug or placebo is being taken or at what dosage randomized patients are assigned different treatments based on chance placebo-controlled parallel-group study is designed to examine the effectiveness and safety of paliperidone ER in adult patients with schizoaffective disorder who are experiencing an acute episode of this disorder Patients in the study will be randomly assigned to 1 of 3 groups to receive 6 weeks of oral treatment with 1 of 2 dosages of paliperidone ER or placebo The primary efficacy outcome will be the change from baseline to Week 6 or the last post-randomization assessment during double-blind treatment endpoint in the PANSS total score Safety will be assessed by monitoring adverse events clinical laboratory testing pregnancy testing vital signs measurements physical examination administration of a 12-lead ECG movement disorders side effect scales and the InterSePT Scale for Suicidal Thinking Patients may also choose to participate in a pharmacogenomic DNA analysis The primary study hypotheses are that at least one of the two dosages of paliperidone ER is better than placebo on the change from baseline in the PANSS total score in acutely ill patients with schizoaffective disorder at the end of 6 weeks of treatment Patients will receive study drug by mouth for a total of 43 days Beginning on Day 1 patients will take either placebo or 1 of 2 doses of paliperidone 6 mgday low randomized dosage or 12 mgday high randomized dosage During the first 2 weeks dosages may be adjusted
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R076477SCA3001 | OTHER | Johnson Johnson Pharmaceutical Research and Development LLC | None |